Literature DB >> 22017839

Clinical evidence for neuroprotection in glaucoma.

M Francesca Cordeiro, Leonard A Levin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22017839      PMCID： PMC3298033          DOI： 10.1016/j.ajo.2011.06.015

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN： 0002-9394            Impact factor:   5.258


× No keyword cloud information.
  8 in total

Review 1.  Neuroprotection in glaucoma - Is there a future role?

Authors:  Abeir Baltmr; James Duggan; Shereen Nizari; Thomas E Salt; M Francesca Cordeiro
Journal:  Exp Eye Res       Date:  2010-08-26       Impact factor: 3.467

2.  Lost in translation: bumps in the road between bench and bedside.

Authors:  Leonard A Levin; Helen V Danesh-Meyer
Journal:  JAMA       Date:  2010-04-21       Impact factor: 56.272

3.  Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma.

Authors:  Luciano Quaranta; Federico Gandolfo; Raffaele Turano; Federico Rovida; Teodoro Pizzolante; Andrea Musig; Enrico Gandolfo
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-07       Impact factor: 4.799

4.  A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study.

Authors:  Theodore Krupin; Jeffrey M Liebmann; David S Greenfield; Robert Ritch; Stuart Gardiner
Journal:  Am J Ophthalmol       Date:  2011-01-22       Impact factor: 5.258

5.  Diurnal and nocturnal effects of brimonidine monotherapy on intraocular pressure.

Authors:  John H K Liu; Felipe A Medeiros; J Rigby Slight; Robert N Weinreb
Journal:  Ophthalmology       Date:  2010-07-21       Impact factor: 12.079

Review 6.  Neuroprotection for treatment of glaucoma in adults.

Authors:  Dayse F Sena; Kanchan Ramchand; Kristina Lindsley
Journal:  Cochrane Database Syst Rev       Date:  2010-02-17

7.  Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group.

Authors: 
Journal:  Am J Ophthalmol       Date:  1998-10       Impact factor: 5.258

Review 8.  Neuroprotection: extrapolating from neurologic diseases to the eye.

Authors:  Helen V Danesh-Meyer; Leonard A Levin
Journal:  Am J Ophthalmol       Date:  2009-05-23       Impact factor: 5.258
  8 in total
  16 in total

Review 1.  Neuroprotection for treatment of glaucoma in adults.

Authors:  Dayse F Sena; Kristina Lindsley
Journal:  Cochrane Database Syst Rev       Date:  2017-01-25

Review 2.  Neuroprotection for treatment of glaucoma in adults.

Authors:  Dayse F Sena; Kristina Lindsley
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

Review 3.  Solving the lost in translation problem: improving the effectiveness of translational research.

Authors:  Ceren Ergorul; Leonard A Levin
Journal:  Curr Opin Pharmacol       Date:  2012-09-11       Impact factor: 5.547

4.  Ocular disposition of the hemiglutarate ester prodrug of ∆⁹-Tetrahydrocannabinol from various ophthalmic formulations.

Authors:  Tushar Hingorani; Goutham R Adelli; Nagendra Punyamurthula; Waseem Gul; Mahmoud A Elsohly; Michael A Repka; Soumyajit Majumdar
Journal:  Pharm Res       Date:  2013-06-05       Impact factor: 4.200

5.  17β-estradiol eye drops protect the retinal ganglion cell layer and preserve visual function in an in vivo model of glaucoma.

Authors:  Katalin Prokai-Tatrai; Hua Xin; Vien Nguyen; Szabolcs Szarka; Balazs Blazics; Laszlo Prokai; Peter Koulen
Journal:  Mol Pharm       Date:  2013-07-23       Impact factor: 4.939

Review 6.  Contribution of microglia-mediated neuroinflammation to retinal degenerative diseases.

Authors:  Maria H Madeira; Raquel Boia; Paulo F Santos; António F Ambrósio; Ana R Santiago
Journal:  Mediators Inflamm       Date:  2015-03-22       Impact factor: 4.711

7.  Adenosine A2AR blockade prevents neuroinflammation-induced death of retinal ganglion cells caused by elevated pressure.

Authors:  Maria H Madeira; Filipe Elvas; Raquel Boia; Francisco Q Gonçalves; Rodrigo A Cunha; António Francisco Ambrósio; Ana Raquel Santiago
Journal:  J Neuroinflammation       Date:  2015-06-10       Impact factor: 8.322

Review 8.  Role of microglia adenosine A(2A) receptors in retinal and brain neurodegenerative diseases.

Authors:  Ana R Santiago; Filipa I Baptista; Paulo F Santos; Gonçalo Cristóvão; António F Ambrósio; Rodrigo A Cunha; Catarina A Gomes
Journal:  Mediators Inflamm       Date:  2014-07-16       Impact factor: 4.711

9.  Caffeine administration prevents retinal neuroinflammation and loss of retinal ganglion cells in an animal model of glaucoma.

Authors:  Maria H Madeira; Arturo Ortin-Martinez; Francisco Nadal-Nícolas; António F Ambrósio; Manuel Vidal-Sanz; Marta Agudo-Barriuso; Ana Raquel Santiago
Journal:  Sci Rep       Date:  2016-06-08       Impact factor: 4.379

Review 10.  New trends in glaucoma risk, diagnosis & management.

Authors:  Thomas Kersey; Colin I Clement; Phillip Bloom; M Francesca Cordeiro
Journal:  Indian J Med Res       Date:  2013-04       Impact factor: 2.375
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.